Related Experiment Video
Updated: Feb 14, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
Decellularized Pulmonary Homograft Repair of Idiopathic Main Pulmonary Artery Aneurysm in SC Hemoglobinopathy
Michael Hikaru Mikami1, Clara Mayumi Mikami2, Lucas do Valle Ciccozzi1
1Cardiovascular Surgery, Hospital Santa Casa de Misericórdia de Curitiba, Curitiba, Brazil.
Background:
Pulmonary artery aneurysm is a rare and potentially fatal condition, often diagnosed incidentally. The lack of specific guidelines makes it difficult to define clear intervention criteria and the ideal reconstructive technique. Decellularized pulmonary homografts (DPHs) have emerged as a promising alternative, although they are still scarcely reported.
Case Summary:
A 48-year-old previously healthy man presented with mediastinal widening on a routine chest x-ray. Work-up revealed an idiopathic main pulmonary aneurysm measuring 52 mm, associated with moderate pulmonary valve stenosis. He underwent aneurysm resection and valve replacement with a DPH (size 25). The immediate postoperative course was satisfactory, but he developed severe pneumonia and was incidentally diagnosed with SC hemoglobinopathy.
Discussion:
The use of a DPH was appropriate in this setting, particularly considering the patient's age and the presence of SC hemoglobinopathy, a condition associated with increased risk of pulmonary hypertension, thrombotic events, and vascular inflammation. Follow-up demonstrated a competent graft with no thromboembolic complications, reinforcing the potential benefit of this technique.
Take-Home Message:
This case highlights the use of a DPH as a safe and effective surgical option for an idiopathic main pulmonary artery aneurysm, especially in patients with associated hematologic conditions, emphasizing the importance of strict follow-up and individualized therapeutic strategies.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

